Coherus Oncology, Inc. (CHRS): Nasdaq/NYSE listing notice — Coherus Oncology receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Coherus Oncology, Inc.

On June 30, 2025, Nasdaq notified Coherus that its common stock closed below $1.00 for 30 consecutive business days.
Company has until December 29, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by deadline, Coherus may qualify for an additional 180-day period by transferring to Nasdaq Capital Market.
Failure to cure could lead to delisting; company intends to monitor bid price and evaluate options.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Coherus Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1).The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market. In accordance with Nasdaq Listi

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-009085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.